Who are FK199B's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MP-513, LJPC-501, EN3267, HBM9036 0.25% Ophthalmic Solution, KK8398.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fk199b.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

FK199B — Competitive Intelligence Brief

FK199B (FK199B) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: C5a receptor antagonist. Area: Immunology.

phase 3 C5a receptor antagonist C5a receptor (C5aR) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

FK199B (FK199B) — Astellas Pharma Inc. FK199B is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FK199B TARGET	FK199B	Astellas Pharma Inc	phase 3	C5a receptor antagonist	C5a receptor (C5aR)
MP-513	MP-513	Tanabe Pharma Corporation	phase 3	Complement C5a receptor antagonist	C5a receptor (C5aR)
LJPC-501	LJPC-501	La Jolla Pharmaceutical Company	phase 3	Complement C5a receptor antagonist	C5a receptor (C5aR)
EN3267	EN3267	Kyowa Kirin Co., Ltd.	phase 3	C5a receptor antagonist	C5aR1 (C5a receptor 1)
HBM9036 0.25% Ophthalmic Solution	HBM9036 0.25% Ophthalmic Solution	Harbour BioMed (Guangzhou) Co. Ltd.	phase 3	C5a receptor antagonist	C5aR (C5a receptor)
KK8398	KK8398	Kyowa Kirin Co., Ltd.	phase 3	Complement C5a receptor antagonist	C5aR1 (C5a receptor 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (C5a receptor antagonist class)

Astellas Pharma Inc · 2 drugs in this class
Astellas Pharma Europe B.V. · 1 drug in this class
Harbour BioMed (Guangzhou) Co. Ltd. · 1 drug in this class
Kyowa Kirin Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FK199B — Competitive Intelligence Brief. https://druglandscape.com/ci/fk199b. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab